Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Globe Newswire•27/08/2026•16:05 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.